Takeaway

• Ravidasvir plus sofosbuvir demonstrated favorable safety and efficacy and was well-tolerated in patients with hepatitis C virus (HCV) infection, including difficult-to-treat populations.

Why this matters

• There is an unmet need for economical direct-acting antivirals for the treatment of HCV infection in low- and middle-income countries.

Study design

• The open-label,...